We are live on ! Find out more
CASC

Cascadian Therapeutics, Inc.
CASC

Delisted

CASC was delisted on the 8th of March, 2018.

Back to rankings

78 hedge funds and large institutions have $168M invested in Cascadian Therapeutics, Inc. in 2017 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 5

165% more capital invested

Capital invested by funds: $63.3M → $168M (+$105M)

150% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 10

37% more funds holding

Funds holding: 57 → 78 (+21)

Holders
78
Holders Change
+21
Holders Change %
+36.84%
% of All Funds
1.94%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
30
Increased
25
Reduced
10
Closed
5
Calls
$741K
Puts
–
Net Calls
+$741K
Net Calls Change
+$202K

Top Buyers

Rank Fund Capital Flow
1
NMC
NEA Management Company
Maryland
+$30.6M
2
BG
Baupost Group
Massachusetts
+$19.1M
3
RG
Redmile Group
California
+$17.1M
4
EC
EcoR1 Capital
California
+$12.6M
5
A
Abingworth
United Kingdom
+$3.89M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$2.29M
2
FO
FT Options
Illinois
-$145K
3
First Eagle Investment Management
First Eagle Investment Management
New York
-$108K
4
VKH
Virtu KCG Holdings
New York
-$97.7K
5
EWM
Edge Wealth Management
New York
-$85K
Name Holding Trade Value Shares
Change 		Change in
Stake
Stifel Financial
51
Stifel Financial
Missouri
$58K – – –
Verition Fund Management
52
Verition Fund Management
Connecticut
$57K +$57.4K +13,660 New
UBS Group
53
UBS Group
Switzerland
$53K +$52.9K +12,576 +5,112%
JP Morgan Chase
54
JP Morgan Chase
New York
$52K +$52.9K +12,583 New
Jacobs Levy Equity Management
55
Jacobs Levy Equity Management
New Jersey
$51K +$52.1K +12,400 New
SG Americas Securities
56
SG Americas Securities
New York
$47K +$48.2K +11,456 New
VKH
57
Virtu KCG Holdings
New York
$46K -$97.7K -23,239 -68%
CS
58
Credit Suisse
Switzerland
$44K +$44.8K +10,650 New
BFM
59
Boothbay Fund Management
New York
$42K +$42.8K +10,187 New
DADC
60
D.A. Davidson & Co
Montana
$27K +$4.35K +1,035 +18%
AIM
61
Acrospire Investment Management
Illinois
$21K -$26.1K -6,210 -55%
TRCT
62
Tower Research Capital (TRC)
New York
$11K +$11.5K +2,742 New
PA
63
Perceptive Advisors
New York
$8K -$2.29M -544,532 -100%
Royal Bank of Canada
64
Royal Bank of Canada
Ontario, Canada
$4K +$17 +4 +0.4%
FDCDDQ
65
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2.69K +$2.73K +650 New
Manulife (Manufacturers Life Insurance)
66
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2K – – –
Group One Trading
67
Group One Trading
Illinois
$1K -$11.6K -2,754 -95%
Citigroup
68
Citigroup
New York
$1K -$139 -33 -17%
Bank of Montreal
69
Bank of Montreal
Ontario, Canada
$1K +$113 +27 +12%
First Eagle Investment Management
70
First Eagle Investment Management
New York
– -$108K -24,999 Closed
EWM
71
Edge Wealth Management
New York
– -$85K -20,000 Closed
TI
72
Trexquant Investment
Connecticut
– -$70K -16,283 Closed
PP
73
Paloma Partners
Connecticut
– -$47K -10,858 Closed
Wells Fargo
74
Wells Fargo
California
– -$2.1K -500 -93%
US Bancorp
75
US Bancorp
Minnesota
– -$4 -1 -33%
1 2
3
4

CASC Hedge Fund Activity: Q1 2017 in Review

78 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q1 2017, worth a combined $168M — up 165% from $63.3M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new CASC positions and 5 closed out — a net gain of 25 holders — while 25 added to existing stakes and 10 trimmed.

The largest buyer was NEA Management Company, adding an estimated $30.6M. The largest seller was Perceptive Advisors, cutting an estimated $2.29M.

  • 78 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q1 2017, up from 57 in Q4 2016.
  • Funds reported $168M of Cascadian Therapeutics, Inc. stock for Q1 2017, up 165% quarter-over-quarter.
  • 30 funds opened new Cascadian Therapeutics, Inc. positions in Q1 2017 and 5 closed out, a net change of +25 holders.
  • The largest Cascadian Therapeutics, Inc. buyer in Q1 2017 was NEA Management Company, an estimated $30.6M added.
  • The largest Cascadian Therapeutics, Inc. seller in Q1 2017 was Perceptive Advisors, an estimated $2.29M sold.

Based on aggregated 13F filings for Q1 2017.